81 related articles for article (PubMed ID: 28109028)
21. A multi-genotype therapeutic human papillomavirus vaccine elicits potent T cell responses to conserved regions of early proteins.
Hancock G; Blight J; Lopez-Camacho C; Kopycinski J; Pocock M; Byrne W; Price MJ; Kemlo P; Evans RI; Bloss A; Saunders K; Kirton R; Andersson M; Hellner K; Reyes-Sandoval A; Dorrell L
Sci Rep; 2019 Dec; 9(1):18713. PubMed ID: 31822717
[TBL] [Abstract][Full Text] [Related]
22. HPV18 E1 Protein Plus
Amador-Molina A; Amador-Molina JC; Arciniega JL; Lizano M
Viral Immunol; 2019; 32(6):269-275. PubMed ID: 31199716
[TBL] [Abstract][Full Text] [Related]
23. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization.
Daemen T; Riezebos-Brilman A; Regts J; Dontje B; van der Zee A; Wilschut J
Antivir Ther; 2004 Oct; 9(5):733-42. PubMed ID: 15535411
[TBL] [Abstract][Full Text] [Related]
24. Induction of immune responses against human papillomaviruses by hypervariable epitope constructs.
Reddy KJ; Banapour B; Anderson DE; Lee SH; Marquez JP; Carlos MP; Torres JV
Immunology; 2004 Jun; 112(2):321-7. PubMed ID: 15147575
[TBL] [Abstract][Full Text] [Related]
25. Effects of the fusion design and immunization route on the immunogenicity of Ag85A-Mtb32 in adenoviral vectored tuberculosis vaccine.
Zhang Y; Feng L; Li L; Wang D; Li C; Sun C; Li P; Zheng X; Liu Y; Yang W; Niu X; Zhong N; Chen L
Hum Vaccin Immunother; 2015; 11(7):1803-13. PubMed ID: 26076321
[TBL] [Abstract][Full Text] [Related]
26. Single-cell cytokine analysis allows detection of cervical T-cell responses against human papillomavirus type 16 L1 in women infected with genital HPV.
Passmore JA; Burch VC; Shephard EG; Marais DJ; Allan B; Kay P; Rose RC; Williamson AL
J Med Virol; 2002 Jun; 67(2):234-40. PubMed ID: 11992584
[TBL] [Abstract][Full Text] [Related]
27. Effective induction of type 1 helper IgG2a and cytotoxic T-cell responses in mice following immunization with human papillomavirus type 16 E2 in MF59.
Heinemann L; Woodfield L; Amer M; Hibma M
Viral Immunol; 2008 Jun; 21(2):225-33. PubMed ID: 18476769
[TBL] [Abstract][Full Text] [Related]
28. DNA vaccines for cervical cancer: from bench to bedside.
Hung CF; Monie A; Alvarez RD; Wu TC
Exp Mol Med; 2007 Dec; 39(6):679-89. PubMed ID: 18160838
[TBL] [Abstract][Full Text] [Related]
29. Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses.
Bourgault Villada I; Moyal Barracco M; Ziol M; Chaboissier A; Barget N; Berville S; Paniel B; Jullian E; Clerici T; Maillère B; Guillet JG
Cancer Res; 2004 Dec; 64(23):8761-6. PubMed ID: 15574788
[TBL] [Abstract][Full Text] [Related]
30. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.
Mikkelsen M; Holst PJ; Bukh J; Thomsen AR; Christensen JP
J Immunol; 2011 Feb; 186(4):2355-64. PubMed ID: 21257961
[TBL] [Abstract][Full Text] [Related]
31. The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens.
Schirmbeck R; Reimann J; Kochanek S; Kreppel F
Mol Ther; 2008 Sep; 16(9):1609-16. PubMed ID: 18612271
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost.
Hulot SL; Korber B; Giorgi EE; Vandergrift N; Saunders KO; Balachandran H; Mach LV; Lifton MA; Pantaleo G; Tartaglia J; Phogat S; Jacobs B; Kibler K; Perdiguero B; Gomez CE; Esteban M; Rosati M; Felber BK; Pavlakis GN; Parks R; Lloyd K; Sutherland L; Scearce R; Letvin NL; Seaman MS; Alam SM; Montefiori D; Liao HX; Haynes BF; Santra S
J Virol; 2015 Jun; 89(12):6462-80. PubMed ID: 25855741
[TBL] [Abstract][Full Text] [Related]
33. CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.
Park JY; Jin DH; Lee CM; Jang MJ; Lee SY; Shin HS; Chung YH; Kim KY; Kim SS; Lee WB; Shin YK; Lee WJ; Park YM; Kim D
J Immunother; 2010 Jun; 33(5):510-22. PubMed ID: 20463596
[TBL] [Abstract][Full Text] [Related]
34. Enhanced immunogenicity of human papillomavirus 16 L1 genetic vaccines fused to an ER-targeting secretory signal peptide and RANTES.
Kim SJ; Lee C; Lee SY; Kim I; Park JS; Sasagawa T; Ko JJ; Park SE; Oh YK
Gene Ther; 2003 Aug; 10(15):1268-73. PubMed ID: 12858192
[TBL] [Abstract][Full Text] [Related]
35. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
36. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
[TBL] [Abstract][Full Text] [Related]
37. CD4+ T cell immunity against the human papillomavirus-18 E6 transforming protein in healthy donors: identification of promiscuous naturally processed epitopes.
Facchinetti V; Seresini S; Longhi R; Garavaglia C; Casorati G; Protti MP
Eur J Immunol; 2005 Mar; 35(3):806-15. PubMed ID: 15719368
[TBL] [Abstract][Full Text] [Related]
38. [Transformation activity and antigenicity of the human papillomavirus type 58 E6E7 fusion gene mutant].
Wang H; Yu JY; Li L
Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):491-6. PubMed ID: 24257298
[TBL] [Abstract][Full Text] [Related]
39. Comparison of HPV DNA vaccines employing intracellular targeting strategies.
Kim JW; Hung CF; Juang J; He L; Kim TW; Armstrong DK; Pai SI; Chen PJ; Lin CT; Boyd DA; Wu TC
Gene Ther; 2004 Jun; 11(12):1011-8. PubMed ID: 14985791
[TBL] [Abstract][Full Text] [Related]
40. Protection of beagle dogs from mucosal challenge with canine oral papillomavirus by immunization with recombinant adenoviruses expressing codon-optimized early genes.
Johnston KB; Monteiro JM; Schultz LD; Chen L; Wang F; Ausensi VA; Dell EC; Santos EB; Moore RA; Palker TJ; Stanley MA; Jansen KU
Virology; 2005 Jun; 336(2):208-18. PubMed ID: 15892962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
